Study to Determine if Taking OTC Non-Steroidal Anti-Inflammatory Affects Eye Pressure in Patients Using Glaucoma Drops - Full Text View

Purpose

The Purpose of This Study is to Determine if Taking an Over the Counter Non-Steroidal Anti-Inflammatory(Ibuprofen)has an Effect on Eye Pressure in Patients using Brimonidine(Alphagan)and Latanoprost(Xalatan) eye drops.

Condition	Intervention
Glaucoma Ocular Hypertension	Drug: ibuprofen, latanoprost, brimonidine Drug: Ibuprofen, brimonidine, latanoprost Drug: Ibuprofen


Study Type:	Interventional
Study Design:	Allocation: Randomized Intervention Model: Crossover Assignment Masking: Investigator Primary Purpose: Treatment
Official Title:	A Prospective,Randomized,Masked,Study to Evaluate the Interaction of Non-Steroidal Anti-Inflammatory Agent With IOP-Lowering Effect of Brimonidine or Latanoprost.

Resource links provided by NLM:

Genetics Home Reference related topics: early-onset glaucoma

MedlinePlus related topics: Glaucoma

Drug Information available for: Ibuprofen Ibuprofen sodium Ibuprofen lysine Brimonidine tartrate Latanoprost

U.S. FDA Resources

Further study details as provided by Philadelphia Eye Associates:

Primary Outcome Measures:

Intra-Ocular Pressure at Day 1 [ Time Frame: 10:00AM ]
Intra-Ocular Pressure at Day 14 [ Time Frame: 10:00AM ]
Intra-Ocular Pressure at Day 21 [ Time Frame: 10:00AM ]
Intra-Ocular Pressure at Day 28 [ Time Frame: 10:00AM ]
Intra-Ocular Pressure at Day 35 [ Time Frame: 10:00AM ]
Intra-Ocular Pressure at Day 49 [ Time Frame: 10:00AM ]
determine if commonly used OTC non-steroidal anti-inflammatory agent,ibuprofen has any effect on the ability of either brimonidine or latanoprost to lower high eye pressure. [ Time Frame: 11 weeks ]


Enrollment:	51
Study Start Date:	December 2006
Study Completion Date:	March 2008
Primary Completion Date:	March 2008 (Final data collection date for primary outcome measure)

Arms	Assigned Interventions
Active Comparator: Latanoprost to determine whether commonly used OTC non-steroidal anti-inflammatory agents taken orally has any effect on the ability of either latanoprost or brimonidine to lower high eye pressure	Drug: ibuprofen, latanoprost, brimonidine to determine whether commonly used OTC non-steroidal anti-inflammatory agents taken orally has any effect on the ability of either latanoprost or brimonidine to lower high eye pressure Other Name: placebo Drug: Ibuprofen, brimonidine, latanoprost to determine whether commonly used OTC non-steroidal anti-inflammatory agentsn(200mg ibuprofen) taken orally has any effect on the ability of either latanoprost or brimonidine to lower high eye pressure Other Name: ibuprofen 200mg, and placebo pills
Active Comparator: Brimonidine to determine whether commonly used OTC non-steroidal anti-inflammatory agents taken orally has any effect on the ability of either latanoprost or brimonidine to lower high eye pressure	Drug: ibuprofen, latanoprost, brimonidine to determine whether commonly used OTC non-steroidal anti-inflammatory agents taken orally has any effect on the ability of either latanoprost or brimonidine to lower high eye pressure Other Name: placebo Drug: Ibuprofen, brimonidine, latanoprost to determine whether commonly used OTC non-steroidal anti-inflammatory agentsn(200mg ibuprofen) taken orally has any effect on the ability of either latanoprost or brimonidine to lower high eye pressure Other Name: ibuprofen 200mg, and placebo pills
Active Comparator: ibuprofen to determine whether commonly used OTC non-steroidal anti-inflammatory agents taken orally has any effect on the ability of either latanoprost or brimonidine to lower high eye pressure	Drug: ibuprofen, latanoprost, brimonidine to determine whether commonly used OTC non-steroidal anti-inflammatory agents taken orally has any effect on the ability of either latanoprost or brimonidine to lower high eye pressure Other Name: placebo Drug: Ibuprofen ibuprofen 200mg Other Name: ibuprofen 200mg

Detailed Description:

Topical IOP-lowering therapy has the advantage of providing a drug level directly to the end organ with very little or no systemic absorption thereby reducing side effect potential. There is very little information in the ophthalmic literature regarding potential drug interactions between topical IOP-lowering medications and other medications taken orally for other medical reasons. Patients will be randomized to either latanoprost or brimonidine. Patients in both groups will be randomized to either placebo or ibuprofen for the first 14 days and then crossed over to the other treatment for 14 days.

Eligibility


Ages Eligible for Study:	21 Years and older (Adult, Senior)
Sexes Eligible for Study:	All
Accepts Healthy Volunteers:	No

Criteria

Inclusion Criteria:

Patients with bilateral or unilateral primary open angle glaucoma or ocular hypertension
An IOP in each eye of greater than 22mm HG after washout of IOP lowering medications
No worse than 20/200 best corrected visual acuity
Normal appearing or non-occludable anterior chamber angles
Discontinuation of current POAG or OH medications before participation in the study.
Written Informed Consent

Exclusion Criteria:

Use of any other ocular medications
Previous ocular surgery or laser therapy within the last three months.
Systemic treatment with any adrenergic agonist or antagonist, corticosteroid or nonsteroidal anti-inflammatory agents(low dose apsirin will be accepted if dose remains the same for entire study period).
An age of less than 21,of child bearing age and currently pregnant, considering pregnancy or a nursing mother.
A history of medical noncompliance or unreliability.
Presence of uncontrolled hypertension, cardiac arrhythmia, cerebrovascular accident, nasal polyps, bleeding diathesis, peptic ulcer disease, gastritis or known intolerance, contraindication or allergy to any drugs used in the study.
Lactose Intolerance.

Contacts and Locations

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00402493

Locations


United States, New Jersey
Philadelphia Eye Associates
Willingboro, New Jersey, United States, 08046
United States, Pennsylvania
Philadelphia Eye Associates
Philadelphia, Pennsylvania, United States, 19134
Philadelphia Eye Associates
Philadelphia, Pennsylvania, United States, 19148

Sponsors and Collaborators

Philadelphia Eye Associates

Pfizer

Investigators


Principal Investigator:	Joseph I. Markoff, Ph.D,M.D	Philadelphia Eye Associates

More Information


Responsible Party:	Philadelphia Eye Associates
ClinicalTrials.gov Identifier:	NCT00402493 History of Changes
Other Study ID Numbers:	GA6110HV
Study First Received:	November 20, 2006
Last Updated:	April 3, 2017

Keywords provided by Philadelphia Eye Associates:


Glaucoma Ocular Hypertension Xalatan Alpahgan Ibuprofen	Non-Steroidal Anti-Inflammatory Brimonidine Latanoprost Eye Pressure Intra-Ocular Pressure

Additional relevant MeSH terms:


Hypertension Glaucoma Ocular Hypertension Vascular Diseases Cardiovascular Diseases Eye Diseases Ibuprofen Anti-Inflammatory Agents, Non-Steroidal Anti-Inflammatory Agents Latanoprost Brimonidine Tartrate Analgesics, Non-Narcotic Analgesics	Sensory System Agents Peripheral Nervous System Agents Physiological Effects of Drugs Antirheumatic Agents Cyclooxygenase Inhibitors Enzyme Inhibitors Molecular Mechanisms of Pharmacological Action Antihypertensive Agents Adrenergic alpha-2 Receptor Agonists Adrenergic alpha-Agonists Adrenergic Agonists Adrenergic Agents Neurotransmitter Agents

ClinicalTrials.gov processed this record on June 26, 2017